secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2021-08-02T23:59:59+00:00
Accession:  0001764013-21-000061
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant receives $200M investment from Roivant at 15% premium to VWAP
------------------------------------------------------------------------

- Roivant purchases 17,021,276 shares at $11.75/share ($200M gross proceeds), a 15% premium to 20-day VWAP.
- Roivant's ownership increases from 57.5% to 63.8%; Immunovant pro forma cash ~$600M.
- Proceeds to fund development of IMVT-1401; pivotal trial for myasthenia gravis planned within 12 months.
- Dr. Frank Torti appointed Executive Chairperson, effective immediately, no additional compensation.
- Investment approved by special committee of independent directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401321000061/0001764013-21-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401321000061/imvt-20210802.htm
  HTML page:      https://secwatch.observer/filing/0001764013-21-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer